Sun Pharma focuses on compliance across its manufacturing units. It aims for full regulatory resolution at facilities facing USFDA action. The company has completed CAPA implementation at Halol. CAPA implementation is in process at Mohali and Dadra. R&D investment is expected to be 6-8% of sales. The company anticipates mid to high single-digit consolidated topline growth in FY26.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.